Immunity following SARS-CoV-2 vaccination in autoimmune neurological disorders treated with rituximab or ocrelizumab

Immunity following SARS-CoV-2 vaccination in autoimmune neurological disorders treated with rituximab or ocrelizumab

BackgroundRituximab (RTX) and ocrelizumab (OCR), B cell-depleting therapy targeting CD20 molecules, affect the humoral immune response after vaccination. How these therapies influence T-cell-mediated immune response against SARS-CoV-2 after immunization remains unclear. We aimed to evaluate the humo...

Full description

Bibliographic Details
Main Authors: Petra Nytrova, Dominika Stastna, Adam Tesar, Ingrid Menkyova, Helena Posova, Helena Koprivova, Veronika Mikulova, Jiri Hrdy, Gabriela Smela, Dana Horakova, Irena Rysankova, Kristyna Doleckova, Michaela Tyblova
Format: Article
Language:English
Published: Frontiers Media S.A. 2023-06-01
Series:Frontiers in Immunology
Subjects:
SARS-CoV-2 mRNA vaccine
SARS-CoV-2
humoral immune response
IFN gamma release assay
myasthenia gravis
multiple sclerosis
Online Access:https://www.frontiersin.org/articles/10.3389/fimmu.2023.1149629/full

Internet

https://www.frontiersin.org/articles/10.3389/fimmu.2023.1149629/full

Similar Items